References
- World Health Organisation. WHO. HIV – estimated antiretroviral therapy coverage among people living with HIV (%) [Internet]. 2022 [cited 2023 Nov 9]. Available from: https://www.who.int/data/gho/data/indicators/indicatordetails/GHO/estimatedantiretroviraltherapycoverageamongpeoplelivingwithhiv(-)#:~:text=Regionalandglobalestimatesare,in2010
- World Health Organisation. WHO. HIV data and statistics [Internet]. [cited 2023 Nov 9]. Available from: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics#:~:text=Asof2022%2C29,hadsuppressedviralloads
- Ssentongo P, Heilbrunn ES, Ssentongo AE, et al. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. Sci Rep. 2021;11(1):6283. doi: 10.1038/s41598-021-85359-3
- Al Meslamani AZ, Sammani N. Assessment of changes in the epidemiology and prognosis of non-SARS-CoV-2 respiratory infections one year after recovery from COVID-19. Respir Investig. 2023;61(4):445–453. doi: 10.1016/j.resinv.2023.03.006
- Al Meslamani AZ. Will SARS-CoV-2 impact the incidence and nature of other respiratory infections? Expert Rev Clin Immunol. 2023 Dec 2; 19(12): 1431–1434. 10.1080/1744666X.2023.2263646
- Danwang C, Noubiap JJ, Robert A, et al. Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis. AIDS Res Ther. 2022 Jan;19(1):3.
- Karmen-Tuohy S, Carlucci PM, Zervou FN, et al. Outcomes among HIV-Positive patients hospitalized with COVID-19. J Acquir Immune Defic Syndr. 2020 Sep;85(1):6–10.
- Lv T, Cao W, Li T. HIV-Related immune activation and inflammation: Current understanding and strategies. J Immunol Res. 2021;2021:7316456. doi: 10.1155/2021/7316456
- Puronen CE, Ford ES, Uldrick TS. Immunotherapy in people with HIV and cancer. Front Immunol. 2019;10:2060. doi: 10.3389/fimmu.2019.02060
- Martin MP, Carrington M. Immunogenetics of HIV disease. Immunol Rev. 2013 Jul;254(1):245–264. doi: 10.1111/imr.12071
- Herbert NG, Goulder PJR. Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment control in children. Curr Opin HIV AIDS. 2023 Sep;18(5):229–236. doi: 10.1097/COH.0000000000000807
- Hu R, Yan H, Liu M, et al. Brief report: Virologic and immunologic outcomes for HIV patients with coronavirus disease 2019. J Acquir Immune Defic Syndr. 2021 Feb;86(2):213–218.
- Ambrosioni J, Blanco JL, Reyes-Urueña JM, et al. Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV. 2021 May 1;8(5): e294–305. 10.1016/S2352-3018(21)00070-9
- Spinelli MA, Jones BLH, Gandhi M. COVID-19 outcomes and risk factors among people living with HIV. Curr HIV/AIDS Rep. 2022 Oct;19(5):425–432. doi: 10.1007/s11904-022-00618-w
- Shalev N, Scherer M, LaSota ED, et al. Clinical characteristics and outcomes in people living with human immunodeficiency virus hospitalized for coronavirus disease 2019. Clin Infect Dis An Off Publ Infect Dis Soc Am. 2020 Nov;71(16):2294–2297.
- Nomah DK, Reyes-Urueña J, Llibre JM, et al. HIV and SARS-CoV-2 Co-infection: epidemiological, clinical features, and Future Implications for clinical Care and Public Health for People Living with HIV (PLWH) and HIV Most-at-Risk Groups. Curr HIV/AIDS Rep. 2021 Dec;18(6):518–526.
- Alavian G, Kolahdouzan K, Mortezazadeh M, et al. Antiretrovirals for prophylaxis against COVID-19: a comprehensive literature review. J Clin Pharmacol. 2021 May;61(5):581–590.
- Mina MJ, Kula T, Leng Y, et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science. 2019 Nov 1;366(6465):599–606. doi: 10.1126/science.aay6485
- Peng X, Ouyang J, Isnard S, et al. Sharing CD4+ T cell loss: when COVID-19 and HIV collide on immune system. Front Immunol. 2020;11:596631. doi: 10.3389/fimmu.2020.596631
- Mondi A, Cimini E, Colavita F, et al. COVID-19 in people living with HIV: clinical implications of dynamics of the immune response to SARS-CoV-2. J Med Virol. 2021 Mar;93(3):1796–1804.
- National Institute of Allergy and Infectious Diseases. SARS-CoV-2 infection weakens immune-cell response to vaccination. [cited 2023 Nov 10]. Available from: https://www.nih.gov/news-events/news-releases/sars-cov-2-infection-weakens-immune-cell-response-vaccination
- Di Castelnuovo A, Costanzo S, Antinori A, et al. Lopinavir/Ritonavir and darunavir/cobicistat in hospitalized COVID-19 patients: findings from the multicenter Italian CORIST study. Front Med. 2021;8:639970. doi: 10.3389/fmed.2021.639970